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Prognostic Value of Estimated Functional Capacity Incremental to
Cardiac Biomarkers in Stable Cardiac Patients
W. H. Wilson Tang, MD; Eric J. Topol, MD; Yiying Fan, PhD; Yuping Wu, PhD; Leslie Cho, MD; Cindy Stevenson, RN; Stephen G. Ellis, MD;
Stanley L. Hazen, MD, PhD
Background-—Few studies have investigated functional capacity self-assessment tools in either prediction of future major adverse
cardiac outcomes beyond all-cause mortality or direct comparisons with clinically available biomarkers.
Methods and Results-—We estimated functional capacity using the Duke Activity Status Index (DASI) questionnaire in 8987
sequential stable patients without acute coronary syndrome who were undergoing elective diagnostic coronary angiography with 3-
year follow-up of major adverse cardiac events (death, nonfatal myocardial infarction, or stroke). A low DASI score provided
independent prediction of a 4.8-fold increase in future risk of incident major adverse cardiac events at 3 years (quartiles 1 versus 4
hazard ratio [95% CI] 4.76 [4.03 to 5.61], P<0.001), and a 3.8-fold increased risk after adjusting for traditional risk factors (3.77
[3.15 to 4.51], P<0.001). The prognostic value of the DASI score was evident in both primary and secondary prevention cohorts,
with and without heart failure, as well as high and low C-reactive protein and B-type natriuretic peptide levels. The DASI score
reclassified 15% of patients (P<0.001) beyond traditional risk factors in predicting future MACE.
Conclusion-—A simple self-assessment tool of functional capacity in stable patients undergoing elective diagnostic cardiac
evaluation provides independent and incremental prognostic value for prediction of both significant coronary angiographic disease
and long-term adverse clinical events. ( J Am Heart Assoc. 2014;3:e000960 doi: 10.1161/JAHA.114.000960)
Key Words: functional capacity impairment • Duke activity status index • prognosis • coronary artery disease
R isk stratification plays an increasing role in contempo-rary management of patients with cardiovascular dis-
ease. Traditionally, the presence of specific clinical signs and
symptoms coupled with abnormalities in cardiac-specific
measurements and estimates of end-organ dysfunction gen-
erates an integrated view of an individual patient’s risk profile.
Recently, the broad acceptance of novel blood-based biomar-
kers has emerged in the arena of risk stratification, even
though the true incremental value of such measures in routine
clinical practice has been challenged in population-based
studies.1,2
Cardiovascular health relies heavily on maintaining appro-
priate dietary behaviors and physical activities.3 The ability
to determine functional capacity has relied on subjective
assessment based on direct patient interviews during the
history and physical examination and objectively by quanti-
fying measures identified from standardized exercise testing.
Standardized instruments to assess functional capacity and/
or health status have been developed,4,5 but their clinical
adoption has been challenged by both logistical hurdles and
an emphasis on “hard” clinical end points in the determi-
nation of treatment responses. Remarkably, few studies
have undertaken the prospective validation of the functional
capacity measures in the prediction of future major adverse
cardiac outcomes beyond all-cause mortality alone or direct
comparisons with clinically available biomarkers. Here,
we sought to determine the prognostic value of estimat-
ing functional capacity using a simple self-administered
assessment tool in a contemporary stable cardiac patient
population.
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Methods
Study Population
The Cleveland Clinic Institutional Review Board approved the
study. The GeneBank study was conducted via prospective
screening of patients aged ≥18 years who underwent elective
coronary evaluation with coronary angiography or computed
tomography between 2001 and 2007. Consecutive patients
were screened and considered for enrollment without inten-
tional exclusion. At the time of enrollment, we excluded
patients who had known acute coronary syndrome within
30 days of enrollment and those who were unable to comply
with or unwilling to follow study protocol. All potentially
eligible patients were approached, and those who agreed to
participate were provided with written informed consent.
Data Synthesis
All clinical characteristics were determined by patient self-
report and confirmed by clinical histories from Electronic
Medical Record. Coronary artery disease (CAD) was defined
as any clinical history of myocardial infarction (MI), percuta-
neous coronary intervention, or coronary artery bypass graft
surgery. Peripheral artery disease (PAD) was defined as a self-
reported history of non-CAD cardiovascular disease and/or
history of or repair of aortic dissection/aneurysm. Self-
reported degree of angina was quantified by Canadian
Cardiovascular Society (CCS) angina classification.6
Assessment of Functional Capacity: The Duke
Activity Status Index Questionnaire
The Duke Activity Status Index (DASI) questionnaire is a self-
assessment tool to estimate functional capacity,7 which
includes 12 activities representative of major aspects of
physical function (personal care, ambulation, household tasks,
sexual function, and recreational activities). It was developed
to predict an individual’s maximal exercise capacity. A score is
calculated based on weighted answers from 12 questions
related to daily activities of living, for which each item is
weighted by its known metabolic cost, and weights of positive
terms are summed to form the individual patient DASI score.
The possible scores range from 0 (all “no” answers) to 58.2
(all “yes” answers). The DASI assessment was prospectively
performed in this study as a predefined assessment of signs
and symptoms related to activities of daily living at the time of
enrollment and was performed by study personnel in a
systematic manner whereby only definitive answers were
scored. Specifically, trained research personnel approached
each patient shortly after informed consent to administer
the DASI questionnaire. Estimated peak oxygen consumption
was calculated according the original formula from Hlatky
and colleagues7: peak VO2 (in mL9kg
19min1)=
0.439DASI+9.6, whereas metabolic equivalent (MET) was
calculated as: 1 MET=3.5 mL9kg19min1 VO2.
Outcome Measures
All 8987 patients were followed prospectively over the
ensuing 3 years by telephone contact, mailing, and medical
record review by designated research personnel independent
of study investigators. All major adverse cardiovascular
events (MACE), defined as death, nonfatal MI, or nonfatal
stroke after enrollment, were adjudicated with source docu-
mentation. Significantly obstructive CAD was defined as any
clinical history of MI, percutaneous coronary intervention,
coronary artery bypass graft surgery, or angiographic evi-
dence of CAD (≥50% stenosis) in ≥1 major coronary artery.
Subsequent MI was adjudicated from source documentation
with supporting evidence including elevated cardiac enzymes,
significant Q-wave definitive electrocardiographic evidence
of new infarction, the presence of myocardial wall akinesis or
scar on imaging, or treatment with thrombolytic agents or
direct percutaneous intervention. Stroke was defined as
documented loss of neurologic function caused by an
ischemic event with residual symptoms continuing ≥24 hours
after onset (not to include transient ischemic attacks,
microvascular infarcts, or amarosis fugax).
Biomarker Analyses
Blood samples were obtained either via venipuncture (in the
case of coronary computed tomography patients) or during
diagnostic coronary angiographic procedure right after arterial
sheath access but before any heparin administration. Blood
samples were immediately processed and frozen at 80°C
until analysis. The biomarker subset included 4805 patients,
for whom stored samples were randomly selected to undergo
biomarker testing in a central core laboratory. Specifically,
high-sensitivity C-reactive protein (hsCRP), B-type natriuretic
peptide (BNP), creatinine, fasting lipid profile, apolipoprotein
A1 (apoA1), and apolipoprotein B (apoB) were all measured in
the Architect ci8200 platform (Abbott Laboratories). Myelop-
eroxidase (MPO) was measured by using the CardioMPO
assay kit (Cleveland Heart Lab). Total leukocyte count was
measured by using the ADVIA 120 Hematology System
(Siemens Medical Systems).
Statistical Analysis
We used the Student’s t test or Wilcoxon–rank sum test for
continuous variables and v2 test for categorical variables for
between-group comparisons. Logistic regression was used to
determine the association with cardiovascular phenotype.
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Cox proportional hazards regression was used for time-to-
event analysis to determine hazard ratio (HR) and 95%
confidence intervals (CIs) for MACE in comparing the highest
with the lowest DASI quartiles for each cohort of interest.
Adjustments were made for individual traditional cardiac risk
factors (including age, sex, low-density and high-density
lipoprotein cholesterol, systolic blood pressure, former or
current cigarette smoking, and diabetes mellitus) to predict
incident 3-year MACE risk. The survival curve was derived
using Kaplan–Meier survival analysis. A cubic spline term of
DASI was fitted in the Cox model to assess how the spectrum
of DASI scores related to the HR of MACE. A nomogram for
MACE based on survival models was constructed (details of
the nomogram construction methods are listed in Data S1 as
previously published8) to visually display the predicted prob-
ability of a MACE event from a multivariate Cox model. Net
reclassification analysis was performed to quantify improve-
ment in models with and without DASI scores. In cutoff values
for net reclassification index estimation,9 we used a ratio of
6:3:1 for low-, medium- and high-risk categories. Comparison
between DASI score and Adult Treatment Panel III score, which
estimates the 10-year risk of developing CAD outcomes (MI or
coronary death),10 was performed by resampling (250 boot-
strap samples from the whole cohort [N=8987]). All data
analyses, including receiver operator characteristic analyses
and area under the curve (AUC) determinations, were sepa-
rately recalculated at each resampling, and the AUCs calcu-
lated from the bootstrap samples were compared. All analyses
were performed using R 2.15.1 software. Values of P<0.05
were considered statistically significant.
Results
Table 1 shows the baseline characteristics of the study
population, which is representative of a contemporary
patient population undergoing elective diagnostic coronary
angiography (see Data S2). The reasons for angiography
included history of positive or indeterminate stress test
(45%), evaluation for possible ischemic causes of symptoms
(63%), preoperative evaluation (15%), and history of cardio-
myopathy (4%). The median DASI score was 38.2 (IQR 24.2
to 50.7), which corresponded to an estimated peak oxygen
consumption of 26 mL/kg per minute (IQR 20 to 31 mL/kg
per minute). As expected, patients with a lower DASI score
were more likely to be older and female and to have an
underlying history of HF, previous MI, or PAD (Table 1). We
observed the association between lower DASI score with
higher likelihood of underlying CAD (quartile 4 versus
quartile 1 of DASI score, unadjusted odds ratio [OR] 2.99,
95% CI 2.59 to 3.46, P<0.01) or PAD (unadjusted OR 5.65,
95% CI 4.74 to 6.73, P<0.01). After adjustment for
traditional risk factors, the association remained statistically
significant (CAD: adjusted OR 2.65, .95% CI 2.22 to 3.15,
P<0.01; PAD: adjusted OR 4.61, 95% CI 3.73 to 5.71,
P<0.01).
The relationship between DASI score and incident
cardiovascular risk is illustrated in Figure 1, in which the
Kaplan–Meier analysis revealed that lower DASI score
(across quartiles of DASI score as well as estimated METs)
is associated with a greater risk of future development of
MACE. Over a 3-year prospective follow-up period, there
were a total of 829 deaths, 404 MIs, and 178 strokes in our
study cohort. We observed that a lower DASI score was
associated with a higher risk of future death, MI, or stroke
(quartile 4 versus quartile 1 of DASI score, unadjusted HR
4.76, 95% CI 4.03 to 5.61, P<0.01). The prognostic value of
DASI score was preserved when adjusted for traditional risk
factors (adjusted HR 3.77, 95% CI 3.15 to 4.51, P<0.01) or
even plus history of heart failure and history of PAD
(adjusted HR 2.89, 95% CI 2.39 to 3.50, P<0.01) and in
cohorts with and without significantly obstructive CAD
(Table 2). These findings were similar across previously
reported METs categories11 (Table 3). As illustrated by the
cubic spline curve, the risk for future MACE appeared to be
steep and linear, with HR significantly above unity, partic-
ularly for DASI scores <38 (or the median, Figure 2). Lower
DASI scores also predicted higher future risk of MACE at
3 years regardless of age, sex, body mass index, diabetes
mellitus, hypertension, lipid status, hsCRP status, or prior MI
(all P<0.01, Figure 3). The prognostic value of DASI score
was also consistent regardless of the clinically assessed
CCS angina class (see Data S3). Use of DASI score over
traditional risk factors was also shown to reclassify patients
(net reclassification index 15%, P<0.001; integrated discrim-
ination improvement 13%, P<0.001; C-statistics 66.5%
versus 71.5%, P<0.001). Direct head-to-head comparison
also demonstrated that DASI score provided more robust
prediction of future development of MACE over a 3-year
period than did the Adult Treatment Panel III score10 (AUC:
0.67 [95% CI 0.66 to 0.69] versus 0.59 [0.57 to 0.60],
P<0.001) in our study population. Combining traditional risk
factors and comorbidities with DASI score, a nomogram is
constructed with a point scoring system indicative of
prospective risk for future MACE at 3 years (Figure 4).
In the subset of patients with biomarkers measured
(n=4805), there were no significant differences in baseline
characteristics compared with those without biomarker
assessment. Lower DASI scores remained prognostically
significant in both high and low levels of fasting lipid profiles,
hsCRP, and BNP, as well as total leukocyte count and MPO.
In fact, the predictive value of DASI score in predicting
future MACE (AUC: 0.67 [95% CI 0.66 to 0.69]) appears to
be comparable with commonly used prognostic cardiac
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biomarkers such as BNP (AUC: 0.68 [95% CI 0.66 to 0.70]
or hsCRP (AUC: 0.61 [95% CI 0.59 to 0.64]). When hsCRP,
BNP, and estimated glomerular filtration rate were all added
to the multivariate model that included traditional risk
factors, lower DASI score (quartile 4 versus quartile 1) still
demonstrated a significant 2-fold increased risk in future
MACE at 3 years (adjusted HR 2.00, 95% CI 1.55 to 2.58,
P<0.01).
Discussion
The key finding of this study is the strong prognostic value
of functional capacity estimated by using a simple 12-
question evaluation tool in a large, contemporary cohort of
stable cardiac patients undergoing coronary angiography.
We observed that the functional capacity estimated with
the DASI score is incremental and superior to that of
Table 1. Baseline Characteristics for Whole Cohort and Across Quartiles of Duke Activity Status Index (DASI) Score
Whole Cohort (n=8987) Quartile 1 (n=2193) Quartile 2 (n=2219) Quartile 3 (n=1597) Quartile 4 (n=2978) P Value*
DASI score <24 24 to 38 38 to 50 ≥51
Age, y 6411 6811 6611 6310 5910 <0.001
Male, % 68 52 65 71 80 <0.001
Smoker, % 66 66 66 68 65 0.214
Diabetes mellitus, % 38 51 42 37 26 <0.001
Hypertension, % 74 81 77 74 65 <0.001
History of CAD, % 68 77 72 66 59 <0.001
History of MI, % 38 47 39 36 32 <0.001
History of HF, % 21 38 22 16 9 <0.001
History of PAD, % 26 38 32 23 15 <0.001
History of stroke, % 7 12 8 5 3 <0.001
History of ventricular
arrhythmia, %
9 11 10 8 8 0.001
LVEF <50% (%) 26 35 28 24 19 <0.001
BMI, kg/m2 28.7 (25.7 to 32.7) 29.4 (25.7 to 34.6) 29 (25.9 to 33.1) 28.7 (25.8 to 32.5) 28.4 (25.5 to 31.6) <0.001
LDL cholesterol, mg/dL 95 (76 to 118) 92 (73 to 114) 94 (75 to 117) 95 (76 to 118) 98 (79 to 120) <0.001
HDL cholesterol, mg/dL 38 (31 to 47) 37 (30 to 47) 38 (31 to 47) 38 (31 to 47) 38 (31 to 48) <0.001
Total cholesterol, mg/dL 165 (142 to 193) 161 (138 to 191) 164 (141 to 191) 164 (143 to 193) 168 (144 to 196) <0.001
Triglycerides, mg/dL 122 (86 to 177) 129 (91 to 187) 122 (88 to 177) 122 (86 to 174) 117 (82 to 170) <0.001
hsCRP, mg/L 2.40 (1.04 to 5.91) 4.13 (1.72 to 10.26) 2.58 (1.12 to 6.03) 2.32 (1.02 to 5.22) 1.58 (0.77 to 3.77) <0.001
eGFR, mL/min per 1.73 m2 83 (67 to 95) 72 (54 to 89) 81 (65 to 93) 86 (71 to 96) 89 (76 to 99) <0.001
MPO, pmol/L 111 (73 to 232) 127 (81 to 277) 112 (74 to 218) 108 (70 to 234) 100 (69 to 207) <0.001
BNP, pg/mL 95 (38 to 242) 176 (75 to 479) 115 (46 to 281) 83 (35 to 178) 58 (26 to 131) <0.001
WBC, 9109/L 6 (5 to 8) 6 (5 to 8) 6 (5 to 8) 6 (5 to 7) 6 (5 to 7) <0.001
apoA1 116 (103 to 132) 115 (101 to 134) 116 (103 to 132) 115 (102 to 131) 115 (104 to 131) <0.001
apoB 81 (69 to 96) 81 (69 to 96) 82 (69 to 95) 82 (69 to 96) 81 (69 to 96) <0.001
Baseline medications
ACE inhibitors/ARBs, % 50 57 52 52 43 <0.001
b-Blockers, % 62 66 64 61 57 <0.001
Statin, % 59 59 60 58 57 0.11
Aspirin, % 72 69 72 72 73 0.005
CAD indicates coronary artery disease; MI, myocardial infarction; HF, heart failure; PAD, peripheral artery disease; LVEF, left ventricular ejection fraction; BMI, body mass index; LDL, low-
density lipoprotein; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; eGFR, estimated glomerular filtration rate; MPO, myeloperoxidase; BNP, B-type natriuretic
peptide; WBC, total leukocyte count; apoA1, apolipoprotein A1; apoB, apolipoprotein B; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker.
*Kruskal–Wallis test for multigroup comparisons.
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traditional cardiovascular risk factors, with or without
underlying heart failure. We further established the associ-
ation between functional capacity estimated by DASI score
and markers of inflammation and oxidative stress in a
subset of patients. Taken together, our findings underscore
the relative importance of objectively determining the
functional capacity for purposes of risk stratification in
cardiac patients.
A B
Figure 1. Kaplan–Meier analysis of Duke Activity Status Index (DASI) scores in predicting future risk of major adverse cardiac events in stable
cardiac patients undergoing elective coronary angiography according to DASI quartiles (A) and estimated metabolic equivalents (METs, B).
Ranges of DASI and METs are the same as for groups in Tables 2 and 3. MI indicates myocardial infarction.
Table 2. Unadjusted and Adjusted Hazard Ratio (HR) for Major Adverse Cardiac Events at 3 Years Stratified According to Quartiles
of DASI Score
Quartile 4 Quartile 3 Quartile 2 Quartile 1
All patients (n=8 987)
Range ≥51 38 to 50 24 to 38 <24
Unadjusted HR 1 1.78 (1.45 to 2.19)* 2.54 (2.12 to 3.03)* 4.76 (4.03 to 5.61)*
Adjusted HR (1) 1 1.58 (1.29 to 1.95)* 2.16 (1.80 to 2.59)* 3.77 (3.15 to 4.51)*
Adjusted HR (2) 1 1.53 (1.24 to 1.89)* 1.87 (1.54 to 2.25)* 2.89 (2.39 to 3.50)*
Event rate 187/2978 176/1597 341/2219 587/2193
Significantly obstructive CAD (n=6 520)
Range ≥51 37 to 51 23 to 37 <23
Unadjusted HR 1 1.63 (1.32 to 2.03)* 2.37 (1.94 to 2.89)* 4.21 (3.51 to 5.06)*
Adjusted HR (1) 1 1.44 (1.16 to 1.78)* 2.06 (1.68 to 2.52)* 3.48 (2.86 to 4.25)*
Adjusted HR (2) 1 1.38 (1.11 to 1.73)* 1.76 (1.43 to 2.17)* 2.66 (2.16 to 3.27)*
Event rate 151/1876 185/1431 287/1584 485/1629
Not significantly obstructive CAD (n=2 467)
Range ≥58 45 to 58 30 to 45 <30
Unadjusted HR 1 1.62 (0.88 to 2.99) 3.32 (1.95 to 5.65)* 5.63 (3.38 to 9.37)*
Adjusted HR (1) 1 1.71 (0.91 to 3.23) 3.58 (2.05 to 6.28)* 5.37 (3.06 to 9.42)*
Adjusted HR (2) 1 1.76 (0.92 to 3.35) 3.42 (1.92 to 6.08)* 4.66 (2.59 to 8.40)*
Event rate 18/676 24/558 56/645 85/588
Model 1: adjusted for traditional risk factors including age, sex, systolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, smoking, and diabetes
mellitus. Model 2: adjusted for Model 1 plus history of heart failure and peripheral artery disease. CAD indicates coronary artery disease; DASI, Duke Activity Status Index.
*P<0.01.
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Although the DASI questionnaire was developed over 2
decades ago, the primary focus in using this self-assessment
tool thus far has been to estimate functional capacity in the
setting of preoperative evaluation or prediction of underlying
ischemia.7,12,13 While the original objective of DASI was to
estimate functional capacity, the responses can also be used
to assess physical limitations relevant to an individual’s
quality of life and to potentially uncover significant problems
related to patients who experienced CAD, PAD, or heart
failure. The importance of prognostication of DASI in our
study, particularly with its strong incremental value to
traditional risk factors and cardiac biomarkers, underscores
the need to systematically assess how DASI score can be of
clinical utility. Indeed, the findings of our study may not be
limited to DASI or even to CAD patients, in that other
instruments that assess daily physical activity such as the
RAND Physical Limitation Scale14 or the Kansas City Cardio-
myopathy Questionnaire for heart failure15,16 have also
demonstrated their incremental prognostic utilities and
responses to therapeutic interventions. These latter instru-
ments aim to assess health status and have not been
evaluated as to whether they correlate directly with functional
capacity.17 Interestingly, the design of DASI queries an
individual’s self-perception of his or her functional capacity
(ie, what an individual is able to do) rather than a direct recall
of prior physical activities and/or limitations. Therefore, the
DASI questionnaire may potentially overestimate the actual
functional capacity as illustrated in the validation studies,18
yet this further underscores an even greater importance for a
standardized instrument such as the DASI questionnaire to
Figure 2. Cubic spline curve for hazard ratios for major adverse
clinical events (MACE) at 3 years with Duke Activity Status Index
(DASI) scores.
Figure 3. Subgroup analysis of Duke Activity Status Index
(DASI) scores and future risk of major adverse cardiac events
(MACE) according to standard cardiac biomarkers. Hazard ratio (x-
axis) of 3-year MACE similar to that presented in Table 2 (quartile
4 vs quartile 1 of DASI score) but across subgroups of different
biomarker cutoffs. apoA1 indicates apolipoprotein A1; apoB,
apolipoprotein B; BNP, B-type natriuretic peptide; eGFR, estimated
glomerular filtration rate; HDL, high-density lipoprotein; hsCRP,
high-sensitivity C-reactive protein; LDL, low-density lipoprotein;
MPO, myeloperoxidase; WBC, white blood cell count.
Table 3. Unadjusted and Adjusted Hazard Ratio (HR) for Major Adverse Cardiac Events at 3 Years Stratified According to
Previously Reported Metabolic Equivalents (METs) Categories11
Range 9.9 METs 7.5 to 9.8 METs 4.8 to 7.4 METs 1.0 to 4.7 METs
Unadjusted HR 1 1.88 (1.46 to 2.42)* 3.63 (2.87 to 4.6)* 6.86 (5.38 to 8.75)*
Adjusted HR (1) 1 1.63 (1.25 to 2.11)* 2.86 (2.23 to 3.66)* 5.21 (4.00 to 6.79)*
Adjusted HR (2) 1 1.64 (1.25 to 2.14)* 2.47 (1.91 to 3.21)* 3.97 (3.00 to 5.26)*
Event rate 79/1593 264/2839 562/3253 386/1302
Model 1: adjusted for traditional risk factors including age, sex, systolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and smoking, diabetes
mellitus. Model 2: adjusted for model 1 plus history of heart failure and peripheral artery disease.
*P<0.01.
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estimate functional capacity when the ability to reclassify risk
may be up to 15% as shown in our study.
While the prognostic value for functional capacity as
determined by standardized exercise testing has been well
established, the requirements of testing skills, equipment, and
experience often hinder broad adoption. At the other end of
the spectrum, simple grading systems such as New York
Heart Association Classification and CCS angina classification
have aided physicians in communicating the degrees of
symptomatic severity, yet they are often subjective and
imprecise. Hence, the ability for a series of questions that can
be collected at the bedside (or adapted to remote monitoring
devices or portals) to risk stratify patients for future MACE
above and beyond established prognostic cardiac biomarkers
speaks to the enduring importance of bedside evaluation of
patient-centered reporting of functional limitations in the era
of biomarker testing. Our findings also highlight the limita-
tions of any clinical or biochemical measure to adequately
quantify functional limitations that may be more meaningful
to patients. Based on our findings, the quest is to examine
what treatment strategies (eg, the ability to detect impaired
functional capacity as a target of physical training and cardiac
rehabilitation) can be effectively incorporated in those
patients with low DASI scores to improve their perceived or
objective functional capacity and to determine whether such
interventions can modify the natural history of the disease.
Few studies have directly examined the potential use of
DASI to predict long-term adverse cardiovascular risk in a
broad patient population with stable cardiac disease. Indeed,
the Women’s Ischemia Syndrome Evaluation (WISE) study was
one of the first studies to identify that functional impairment
estimated by the DASI correlates with indeterminate exercise
test results and is associated with an adverse prognosis
among women with suspected myocardial ischemia.11 Surgi-
cal studies also illustrated the finding that poor functional
capacity estimated by DASI following cardiac surgery identi-
fies patients who are at risk for reduced long-term survival.19
Of note, the relationship between DASI score and risk was
linear and extended to the higher functional capacity end
(higher score). Thus, those who achieved a maximum baseline
DASI demonstrated better risk-adjusted long-term survival
(HR 0.64; 95% CI 0.50 to 0.83; P=0.0005).19 Such a finding is
consistent with improved overall survival conferred by
improved functional capacity achieved during cardiac rehabil-
itation in the post cardiothoracic surgical setting.19 In the
setting of heart failure or chronic kidney disease, the ability to
assess functional status and prognosis has been demon-
strated.18,20 Recent data from a large heart failure cohort
further implied that those with changes in DASI scores over
1 year demonstrated stronger association with long-term
outcomes than objective assessment (6-minute walk dis-
tance).21 These findings are supportive of the ability of
improving DASI score as a potential therapeutic target. Future
investigations into potential benefits of using DASI scores
(especially those with DASI <38) to triage cardiac evaluation
and guide therapeutic interventions, such as more in-depth
evaluation of disability, more aggressive secondary prevention
strategies, more intensive cardiac rehabilitation, or closer
outpatient follow-up, are therefore warranted for this higher-
risk population.
Despite one of the largest studies conducted to date on
the prognostic value of DASI and functional capacity in the
Figure 4. Nomogram for estimating risk of major adverse cardiac events (MACE) incorporating Duke
Activity Status Index (DASI) score with traditional risk factors. Methodology as described in Data S1. HDL
indicates high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure.
DOI: 10.1161/JAHA.114.000960 Journal of the American Heart Association 7
DASI Score and Cardiovascular Risk Tang et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on June 14, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
cardiovascular population, our study has several limitations.
The large sample size is reassuring regarding how the results
can be generalized, although it may not be completely
generalizable beyond the setting of coronary evaluation due to
referral and ascertainment bias at the point of recruitment
and study (ie, cardiac catheterization laboratory). There are
also several notable limitations. First, while DASI has been
validated in the past as a measure of metabolic capacity and
function, there is no objective validation of functional capacity
measurement in our large cohort besides angina class, and
the ability to respond to the questions is required (thus
excluding those that were unable to complete the question-
naires due to their underlying diseases or functional or
communication limitations). We did not systematically collect
baseline or interim information regarding history of atrial
fibrillation and stroke in those enrolled. Second, we only have
biochemical analyses on roughly half of the study cohort,
although there is still adequate power to determine the
incremental prognostic value of the DASI score. Third,
although we have provided subgroup assessment in the
non–heart failure and non-PAD cohorts (potential confounding
effect due to underlying cardiac and vascular insufficiency),
we cannot exclude other reasons that affect an individual’s
functional limitations. Nevertheless, this also speaks to the
power of this simple questionnaire that can depict risks that
are otherwise unaccounted for, such as frailty, deconditioning,
or psychosocial issues. Last, the fact that there is only a
single time-point assessment may require further studies to
determine if improvement in DASI score can be associated
with improvement in short- and long-term prognosis as
implied in the postsurgical or heart failure literature or with
treatment strategies such as cardiac rehabilitation.19 We
would also like to emphasize that the nomogram is largely
derived to highlight the relative clinical contributions of DASI
to the overall prognostic value when other factors of
functional capacity are under consideration. All patients were
used in deriving the score, and further validation of this score
is warranted in an independent study population.
Conclusion
The DASI, a self-assessment tool of functional capacity,
provides strong independent and incremental prognostic
value for long-term adverse clinical events that is comparable
to cardiac biomarkers in stable cardiac patients undergoing
coronary evaluation.
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 2 
Supplement 1: Nomogram Development 
 
A built-in function in the statistical R package, nomogram, was used to construct the 
nomogram1-3. Absolute beta values are ranked based on the estimated regression 
coefficients.  First step is to determine which predictor has the biggest impact in the 
model. Then, the next step is to sequentially assign scores to other predictors based on 
their proportions to the point assigned to the most important predictor.  Estimated beta 
coefficients from a Cox model were used as followed: 
 
Predictor Level Beta Values Absolute 
maximum beta 
value 
Rank  
Age Unit=1 0.0381 10 to 
100 by 
10 
0.0381*(100-
10) = 3.429 
1 100 assigned to 
age=100; 
0 assigned to age=10; 
Assign points to other 
age values based on the 
linear interpolation 
HDL Unit=1 -0.0063 0 to 
180 by 
20 
0.0063*(180-
0) =1.134 
2 100*(1.134/3.429)=33 
assigned to HDL=0; 
0 assigned to HDL=180; 
Assign points to other 
HDL values based on 
the linear interpolation 
Smoking 1 0.2368 0, 1 0.2368 3 100*(0.2368/3.429)=7 
assigned to smokers 
Gender Male -0.0499 Female, 
Male 
0.050 4 100*(0.05/3.429)=1 
assigned to female 
 
 
The Cox model used age, gender, HDL, and smoking as predictors.  Steps of assigning 
scores to each predictor are shown below. 
1) Age (Continuous variable): The range of age values is chosen to be the minimum 
and maximum values that will be displayed on the nomogram, which is 0 and 100 in 
this case. The calculated absolute maximum beta value=0.0381(100-10)=3.429.  In 
comparison to the maximum beta value of Gender (0.05), HDL (1.134), and smoking 
(0.2368), age has the biggest impact on the risk of the event. So we assign 100 to 
age=100, and 0 to age=0 and points to other age values based on the linear 
interpolation. 
 
2) Gender (categorical variable with two levels):  The total point of the factor gender is 
assigned based on its proportion to the total point of the age=100 (point=100).  The 
formula is: Total point of male =100*(absolute maximum beta value for gender/ 
absolute maximum beta value for age) =100*(0.05/3.429)=1 
So a male patient is assigned 1 point, whereas 0 for a female patient. 
 3 
3) HDL (continuous variable): The range for HDL is from 0 to 180.  The total point 
assigned to HDL is 100*(1.134/3.429)=33.  So 33 is assigned to HDL=0 and 0 
assigned to HDL=180 and points assigned to other HDL values based on the linear 
interpolation. 
 
Reference: 
1) Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, 
Logistic Regression, and Survival Analysis (Springer Series in Statistics). Springer, 
New York, NY, 2001. 
2) Harrell FE. rms: Regression Modeling Strategies. R package version 3.6-3, 2013.  
3) Iasonos A1, Schrag D, Raj GV, Panageas KS. How to build and interpret a 
nomogram for cancer prognosis. J Clin Oncol. 2008;26:1364-1370.  
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Supplement 3: Unadjusted and adjusted Hazard ratio (HR) for Major Adverse Cardiac Events at 3 years According to 
Canadian Cardiovascular Society (CCS) Angina Class 
 Quartile 4 Quartile 3 Quartile 2 Quartile 1 
CCS Class 0 (n=231) 
Range ≥51 42-51 25-42 <25 
Unadjusted HR 1 1.48 (0.49-4.51) 2.34 (0.97-5.64) 3.13 (1.32-7.40)** 
Adjusted HR 1 1.32 (0.43-4.03) 2.4 (0.93-6.15) 3.22 (1.26-8.22)* 
Event rate 9.9% 14.3% 22.4% 28.1% 
CCS Class I (n=2,827) 
Range ≥51 43-51 27-43 <27 
Unadjusted HR 1 1.80 (1.22-2.65)** 2.99 (2.19-4.08)*** 5.55 (4.20-7.35)*** 
Adjusted HR 1 1.63 (1.09-2.42)* 2.62 (1.89-3.62)*** 4.60 (3.35-6.31)*** 
Event rate 5.8% 10.4% 16.7% 28.9% 
CCS Class II (n=2,102) 
Range ≥51 39-51 27-39 <27 
Unadjusted HR 1 1.93 (1.25-2.99)** 1.99 (1.33-2.99)*** 4.59 (3.19-6.60)*** 
Adjusted HR 1 1.75(1.13-2.72)* 1.66(1.10-2.51)* 3.68 (2.52-5.38)*** 
Event rate 5.7% 11.0% 11.4% 23.9% 
 6 
CCS Class III (n=1,178) 
Range ≥46 34-46 19-34 <19 
Unadjusted HR 1 0.81 (0.48-1.38) 2.13 (1.38-3.27)*** 2.97 (1.94-4.55)*** 
Adjusted HR 1 0.71 (0.42-1.21) 1.64 (1.04-2.60)* 2.15 (1.33-3.47)** 
Event rate 10.1% 8.5% 20.6% 26.5% 
CCS Class IV (n=2,176) 
Range ≥51 35-51 21-35 <21 
Unadjusted HR 1 2.39 (1.63-3.50)*** 2.50 (1.66-3.76)*** 5.06 (3.55-7.20)*** 
Adjusted HR 1 2.11 (1.43-3.09)*** 2.10 (1.38-3.18)*** 4.01 (2.74-5.86)*** 
Event rate 6.0% 13.8% 14.3% 26.9% 
 
Adjusted for traditional risk factors include age, gender, systolic blood pressure, low-density lipoprotein cholesterol, high-density 
lipoprotein cholesterol, smoking, diabetes mellitus.  * p<0.05; **p<0.01; ***p<0.001 
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